Half-year report · Q2
3341.TEDINET S100URMJ
Period2024-04-01 → 2024-09-30
Filed2024-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥175.6bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥340.3bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥166.3bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Operating income | ¥423m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | ¥3.4bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | ¥772m | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥9.4bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.4bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥762m | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥3.4bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥43m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.6bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.7bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥43m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | ¥1.7bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥204.1bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥195.1bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥193.5bn | at 2023-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥146.3bn | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥136.7bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥57.9bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥58.4bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥57.9bn | at 2023-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥26.4bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥26.0bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥26.4bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥26.0bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥22.2bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥23.8bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.6bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥20.4bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥11.9bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥6.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥13.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥8.0bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥4.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥4.4bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥5.4bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-1.44 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥85.35 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥58.44 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 28.3% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 29.9% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 29.9% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 36
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥6.6bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥6.6bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥4.2bn |
| jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥156.6bn |
| jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥156.6bn |
| jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥4.5bn |
| jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥6.0bn |
| jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥5.9bn |
| jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥122m |
| jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥766m |
| jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥19.6bn |
| jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥13.1bn |
| jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥6.5bn |
| jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥652m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥182.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥175.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥6.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥4.6bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥6.7bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥6.7bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥3.5bn |
| jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥147.6bn |
| jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥147.6bn |
| jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥6.0bn |
| jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥4.9bn |
| jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥4.9bn |
| jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥14m |
| jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥698m |
| jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥20.5bn |
| jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥13.8bn |
| jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥6.7bn |
| jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥167m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥173.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥166.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥6.7bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥6.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 520
| Item | Context | Value | Unit |
|---|---|---|---|
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts for operation (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus | |
| Issued shares total number of shares etc (text) | FilingDateInstant | Text · Plus | |
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所(プライム市場) | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)単元株式数100株(注) | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus | |
| Major shareholders (text) | FilingDateInstant | Text · Plus | |
| Name major shareholders | CurrentQuarterInstant_No1MajorShareholdersMember | Original text (Japanese)三津原 庸介 | |
| Address major shareholders | CurrentQuarterInstant_No1MajorShareholdersMember | Original text (Japanese)東京都渋谷区 | |
| Name major shareholders | CurrentQuarterInstant_No2MajorShareholdersMember | Original text (Japanese)三津原 博 | |
| Address major shareholders | CurrentQuarterInstant_No2MajorShareholdersMember | Original text (Japanese)東京都港区 | |
| Name major shareholders | CurrentQuarterInstant_No3MajorShareholdersMember | Original text (Japanese)株式会社三津原興産 | |
| Address major shareholders | CurrentQuarterInstant_No3MajorShareholdersMember | Original text (Japanese)東京都港区西麻布4丁目19-6 | |
| Name major shareholders | CurrentQuarterInstant_No4MajorShareholdersMember | Original text (Japanese)合同会社マックスプランニング | |
| Address major shareholders | CurrentQuarterInstant_No4MajorShareholdersMember | Original text (Japanese)東京都港区西麻布4丁目19-6 | |
| Name major shareholders | CurrentQuarterInstant_No5MajorShareholdersMember | Original text (Japanese)日本マスタートラスト信託銀行株式会社(信託口) | |
| Address major shareholders | CurrentQuarterInstant_No5MajorShareholdersMember | Original text (Japanese)東京都港区赤坂1丁目8番1号 赤坂インターシティAIR | |
| Name major shareholders | CurrentQuarterInstant_No6MajorShareholdersMember | Original text (Japanese)日本調剤従業員持株会 | |
| Address major shareholders | CurrentQuarterInstant_No6MajorShareholdersMember | Original text (Japanese)東京都港区芝5丁目33-11 田町タワー9階 | |
| Name major shareholders | CurrentQuarterInstant_No7MajorShareholdersMember | Original text (Japanese)三津原 陽子 | |
| Address major shareholders | CurrentQuarterInstant_No7MajorShareholdersMember | Original text (Japanese)東京都港区 | |
| Name major shareholders | CurrentQuarterInstant_No8MajorShareholdersMember | Original text (Japanese)姚 恵子 | |
| Address major shareholders | CurrentQuarterInstant_No8MajorShareholdersMember | Original text (Japanese)東京都港区 | |
| Name major shareholders | CurrentQuarterInstant_No9MajorShareholdersMember | Original text (Japanese)MSIP CLIENT SECURITIES (常任代理人 モルガン・スタンレーMUFG証券株式会社) | |
| Address major shareholders | CurrentQuarterInstant_No9MajorShareholdersMember | Text · Plus | |
| Name major shareholders | CurrentQuarterInstant_No10MajorShareholdersMember | Text · Plus | |
| Address major shareholders | CurrentQuarterInstant_No10MajorShareholdersMember | Text · Plus | |
| Issued shares voting rights (text) | FilingDateInstant | Text · Plus | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | - | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | - | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | - | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | - | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | - | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | Original text (Japanese)一単元(100株)未満の株式 | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)日本調剤株式会社 | |
| Address of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)東京都港区芝5丁目33-11 | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYTDDuration | Text · Plus | |
| Type1 semi annual consolidated financial statements financial information | CurrentYTDDuration | Text · Plus | |
| Note on independent audit financial information | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of income (text) | CurrentYTDDuration | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |